Symbiotix Biotherapies, Inc. is a privately-held biopharmaceutical company headquartered in Boston, Massachusetts that is developing a novel class of molecular therapeutics based on the human microbiome. Our company’s scientific founders are several of the world’s leading researchers in the microbiome field, and we are commercializing technology that has been developed over many years at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology and Dartmouth College. We are moving forward a capital-efficient virtual R&D model that leverages the capabilities of academic laboratories, contract research organizations and partner organizations.